HK1207796A1 - Glufosfamide combination therapies for cancer - Google Patents

Glufosfamide combination therapies for cancer

Info

Publication number
HK1207796A1
HK1207796A1 HK15108524.1A HK15108524A HK1207796A1 HK 1207796 A1 HK1207796 A1 HK 1207796A1 HK 15108524 A HK15108524 A HK 15108524A HK 1207796 A1 HK1207796 A1 HK 1207796A1
Authority
HK
Hong Kong
Prior art keywords
cancer
combination therapies
glufosfamide
glufosfamide combination
therapies
Prior art date
Application number
HK15108524.1A
Other languages
English (en)
Chinese (zh)
Inventor
Edwin J Thomas
Matthew Parris
Forrest H Anthony
Original Assignee
Eleison Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleison Pharmaceuticals LLC filed Critical Eleison Pharmaceuticals LLC
Publication of HK1207796A1 publication Critical patent/HK1207796A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15108524.1A 2012-04-19 2015-09-01 Glufosfamide combination therapies for cancer HK1207796A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261687114P 2012-04-19 2012-04-19
PCT/US2012/053275 WO2013158143A1 (en) 2012-04-19 2012-08-31 Glufosfamide combination therapies for cancer

Publications (1)

Publication Number Publication Date
HK1207796A1 true HK1207796A1 (en) 2016-02-12

Family

ID=49380659

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108524.1A HK1207796A1 (en) 2012-04-19 2015-09-01 Glufosfamide combination therapies for cancer

Country Status (7)

Country Link
US (1) US20130281386A1 (xx)
EP (1) EP2846638A4 (xx)
JP (3) JP2015514756A (xx)
CN (1) CN104270944A (xx)
CA (1) CA2870138A1 (xx)
HK (1) HK1207796A1 (xx)
WO (1) WO2013158143A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016134486A1 (en) * 2015-02-27 2016-09-01 Steinberg Gregory Use of canagliflozin and derivatives thereof in the treatment of cancer
CN105030798B (zh) * 2015-06-24 2017-11-24 李宏 一种抗肿瘤的药物组合物及其制备方法和应用
US20210283100A1 (en) * 2016-08-01 2021-09-16 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer
WO2019105149A1 (zh) * 2017-11-28 2019-06-06 深圳艾欣达伟医药科技有限公司 葡磷酰胺的抗癌医药用途
JP7414230B2 (ja) * 2018-11-09 2024-01-16 国立大学法人 琉球大学 抗血液悪性腫瘍薬
WO2020170240A1 (en) 2019-02-21 2020-08-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
CN110038009B (zh) * 2019-05-13 2021-01-08 浙江大学 卡格列净在制备抗肿瘤药物中的应用
KR102437311B1 (ko) * 2019-12-03 2022-09-15 주식회사 하임네이처 Ndpk 활성제 및 sglt-2 억제제를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20210084919A (ko) * 2019-12-30 2021-07-08 주식회사 하임바이오 Sglt-2 억제제 및 고시폴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
WO2022044014A1 (en) * 2020-08-26 2022-03-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Combination therapy for reducing drug-induced nephrotoxicity, dyslipidemia and hyperglycemia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
WO2003082301A1 (en) * 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
WO2004081181A2 (en) * 2003-03-07 2004-09-23 Threshold Pharmaceuticals, Inc. Method for determining susceptibility of tumor to treatment with anti-neoplastic agent
EP1883298A1 (en) * 2005-05-11 2008-02-06 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
US8450286B2 (en) * 2008-03-18 2013-05-28 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof

Also Published As

Publication number Publication date
CA2870138A1 (en) 2013-10-24
JP2018087228A (ja) 2018-06-07
EP2846638A1 (en) 2015-03-18
US20130281386A1 (en) 2013-10-24
EP2846638A4 (en) 2016-03-02
CN104270944A (zh) 2015-01-07
JP2015514756A (ja) 2015-05-21
JP2020055884A (ja) 2020-04-09
WO2013158143A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
HK1223552A1 (zh) 用於癌症的組合療法
IL254716A0 (en) Zinc-lysine conjugate
HK1211475A1 (en) Combination therapy
EP2934531A4 (en) COMBINATION
GB201208309D0 (en) Complexes
HK1207796A1 (en) Glufosfamide combination therapies for cancer
EP2853789A4 (en) SLIDING PART
PL2935741T3 (pl) Mechanizm ryglujący
HK1210049A1 (en) Combination therapies for treating cancer
EP2896853A4 (en) SLIDING ELEMENT
PT2914254T (pt) Terapias de combinação para tratar cancros quimiorresistentes
GB201218996D0 (en) Improved panel
EP2911673A4 (en) COMBINATION
GB201217439D0 (en) Combination therapy
EP2882792A4 (en) POLYCARBONATE
GB201320563D0 (en) Anti-infection unit
GB2504567B (en) Anti-Relatch Mechanism
HK1210426A1 (en) Combination therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
HU4381U (en) Arrangement for divided enery-production
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
GB2500605B (en) Lock mechanism
HK1212895A1 (zh) 用於免疫調節的沙奎那韋-
EP2925728A4 (en) COMBINATION
GB201304493D0 (en) Not published